Epigenetic therapy--a new development in pharmacology.
Epigenetics, heritable changes in gene expression that do not involve changes in DNA sequence, is known to be involved in disease. Two important epigenetic changes that are known to contribute to disease are abnormal methylation patterns of DNA and modifications of histones in chromatin. This review describes a new development in pharmacology, epigenetic therapy, which attempts to correct these changes. At present two groups of drugs are being developed. One inhibits DNA methyltransferases (DNMTs) resulting in the inhibition of DNA methylation. This group of drugs may prove to be useful in the treatment of cancer where hypermethylation of tumour suppressor genes is known to lead to silencing of these genes. The other group of drugs inhibits histone deacetylases (HDACs) resulting in the accumulation of acetylated histones which are thought to mediate the anticancer effects of these drugs. Both these drug groups have shown promising results in drug trials for the treatment of cancer. Since epigenetic changes are thought to underlie a wide range of diseases, the scope of epigenetic therapy is likely to expand.
Department of Pharmacology & Clinical Pharmacology, Christian Medical College, Vellore, India. jpeedi@cmcvellore.ac.in
Jacob
J
Peedicayil
D002986:Clinical Trials as Topic; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors / Q000378:metabolism; D015195:Drug Design; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000145:classification / Q000627:therapeutic use*; D044127:Epigenesis, Genetic; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism; D006657:Histones / Q000378:metabolism; D006801:Humans; D008967:Molecular Biology; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D016376:Oligonucleotides, Antisense; D015254:DNA Modification Methylases; D006655:Histone Deacetylases